Nevada Chapter, NBDF
7500 W. Lake Mead Blvd
Suite 9 #458
Las Vegas, NV 89128

Our Mission

The National Bleeding Disorders Foundation (NBDF) Nevada Chapter is dedicated to finding better treatments and cures for inheritable bleeding disorders and to preventing the complications of these disorders through education, advocacy and research.

News & Events

CSL Behring, the biopharmaceutical company behind the hemophilia B gene therapy HEMGENIX ® (etranacogene dezaparvovec-drlb), provided an update to the bleeding disorders community regarding the availability of the treatment. In a letter to the hemophilia B community, the company stated that they have “reestablished limited supply in April 2026,” and that they remain committed to actively managing the existing supply.

In a letter sent to healthcare providers, Ferring Pharmaceuticals announced that STIMATE® (desmopressin acetate) nasal spray is expected to be available in the United States beginning October 2026.

Federal:

Medicaid Work Reporting Requirements

Advertisements

Nevada Chapter, NBDF
7500 W. Lake Mead Blvd
Suite 9 #458
Las Vegas, NV 89128

© National Bleeding Disorders Foundation 2026

Crafted by Firespring